By Fineline Cube 
China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture (JV) with South Korea’s CGBio Co., Ltd. The collaboration aims to advance research in innovative cellular biomaterials and regenerative medicine, with the goal of creating a pioneering medical biotechnology company with independent R&D capabilities and in-house production capacity.
Joint Venture Details
The JV is named Litian (Taicang) Biotechnology Co., Ltd., with a registered capital of RMB 60 million (USD 8.3 million). Under the agreement, Sanyou Medical will contribute RMB 39.6 million (USD 5.5 million), representing a 66% equity stake, while CGBio will contribute RMB 20.4 million (USD 2.8 million) for a 34% equity stake.-Fineline Info & Tech